The estimated Net Worth of Sharon Collins Presnell is at least $1.2 Million dollars as of 8 November 2018. Sharon Presnell owns over 40,000 units of Viveve Medical Inc stock worth over $117 and over the last 12 years he sold VIVE stock worth over $1,199,300. In addition, he makes $0 as Independent Director at Viveve Medical Inc.
Sharon has made over 6 trades of the Viveve Medical Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 40,000 units of VIVE stock worth $50,800 on 8 November 2018.
The largest trade he's ever made was exercising 224,064 units of Viveve Medical Inc stock on 2 August 2012 worth over $17,925. On average, Sharon trades about 18,359 units every 82 days since 2012. As of 8 November 2018 he still owns at least 292,193 units of Viveve Medical Inc stock.
You can see the complete history of Sharon Presnell stock trades at the bottom of the page.
Dr. Sharon Collins Presnell Ph.D. serves as Independent Director of the Company. Dr. Sharon Presnell currently serves as President of the Amnion Foundation, a not-for-profit organization ethically addressing birth tissue-derived cells in regenerative medicine and drug development. Concurrently, she is the founder/owner of CytoStrategy and provides life sciences consulting services to companies and organizations throughout the U.S. and E.U. Holding a B.S in cellular biology and Ph.D. in experimental pathology, Dr. Presnell transitioned from a university faculty position to Director of R&D at Becton Dickinson. Her previous executive leadership positions in the biotech industry include the role of President at Samsara Sciences, Inc., a wholly owned subsidiary of Organovo, Inc. where she held positions as Chief Scientific Officer, Chief Technology Officer and Executive Vice President of R&D. Sharon has served continuously as a scientific, technical, and translational reviewer for the NIH for over 20 years. Her specialty is developing strategies for the successful development of nascent technologies, including considerations of science, organizational structure, and economic factors.
Sharon's mailing address filed with the SEC is , 345 INVERNESS DRIVE S., BLDG B, STE 250, ENGLEWOOD, CO, 80112.
Over the last 8 years, insiders at Viveve Medical Inc have traded over $444,564 worth of Viveve Medical Inc stock and bought 3,021,700 units worth $13,021,042 . The most active insiders traders include Sachs Group Incgoldman Sach..., Daniel Janney und Capital Management, Llcston.... On average, Viveve Medical Inc executives and independent directors trade stock every 80 days with the average trade being worth of $83. The most recent stock trade was executed by Sachs Group Incgoldman Sach... on 30 September 2019, trading 92,425 units of VIVE stock currently worth $444,564.
viveve provides women low risk, high reward medical procedures that promote personal health and wellness. the company is committed to innovative technological advances and to broad and elucidating education for medical and lay audiences worldwide.
Viveve Medical Inc executives and other stock owners filed with the SEC include: